Use of ACTIMMUNE in Patients With ADO2

Completed · Phase 2

Conditions studied: Autosomal Dominant Osteopetrosis Type 2

In brief

This study is an open label use of ACTIMMUNE for patients with Autosomal Dominant Osteopetrosis Type 2(ADO2). Effects of treatment will be evaluated after 14 weeks on ACTIMMUNE by bone resorption markers. This study will treat 12 patients with ADO2 recruited from Indiana University and Riley Hospital for Children at Indiana University Health.

Key facts

Study ID

NCT02584608

Run by

Indiana University

People needed

12

Starts

2016-01-01

Expected to finish

2019-11-12

Last updated by the study team

2021-01-08

Who can join

Age: 3 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject is diagnosed with clinically significant ADO2 as determined by the investigator.
• Individuals will be screened who have either been diagnosed with osteopetrosis and have a clinical phenotype and/or family history that is consistent with ADO2, have been told that they have an abnormally high bone density (>3SD above mean for age and sex), or a clinical presentation consistent with ADO2. Initial contact will be with members of ADO2 kindreds who have known disease.
• Provide written informed consent for competent adults and for minors provide written assent (if appropriate) and written informed consent by a legally authorized representative after the nature of the study has been explained, and prior to any research-related procedures
• Ages 3 to 65 years inclusive.
• Willing to use reliable method of contraception [i.e. oral or patch hormonal contraceptives, intrauterine device, physical barrier methods, tubal ligation or hysterectomy, vasectomy (partner) or abstinence] throughout the study and for 30 days after the last dose of study drug.

You may not qualify if…

• Any unstable illness that in the investigator's opinion precludes participation in the study.
• Serum calcium >10.6 mg/dl at screening.
• eGFR using the MDRD equation in adults (or the modified Schwartz equation for children) of < 35 ml/min/1.73m2.
• Nephrocalcinosis on screening ultrasound Grade 3 or higher [18]. Subjects with grade 3 or higher nephrocalcinosis will be excluded because we anticipate that use of study drug will increase bone resorption, resulting in increased urinary calcium excretion, which could, potentially, lead to worsening nephrocalcinosis. The grading scale is listed below:
• 0 = Normal
• = Faint hyperechogenic rim around the sides and tip of the medullary pyramids
• = More intense echogenic rim with echoes faintly filling the entire medullary pyramid
• = Intense echoes throughout the medullary pyramid
• = Solitary focus of echoes at the tip of the medullary pyramid/nephrolithiasis
• Use of any investigational product (drug or device) within 30 days prior to randomization.
• Subject reported history of hepatitis C.
• A recent (past 5 years) history of alcoholism or intravenous drug abuse.
• History of hypersensitivity to IFN-ɣ or E. coli-derived products.
• History of liver disease as evidenced by laboratory results at Screening (aspartate aminotransferase [AST] or alanine aminotransferase [ALT] >2x the upper limit of normal), except when in the opinion of the investigator the liver disease is caused by extra medullary hematopoiesis.
• Pregnant or nursing women or those who plan on becoming pregnant during the study.

Where it is running

• Indiana University School of Medicine — Indianapolis, Indiana, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.